ES2123432A1 - Formulation for oral delivery of iron complexes - comprises water-soluble adduct comprising polyhydroxylated trivalent iron complex with soluble albumin - Google Patents

Formulation for oral delivery of iron complexes - comprises water-soluble adduct comprising polyhydroxylated trivalent iron complex with soluble albumin

Info

Publication number
ES2123432A1
ES2123432A1 ES9602180A ES9602180A ES2123432A1 ES 2123432 A1 ES2123432 A1 ES 2123432A1 ES 9602180 A ES9602180 A ES 9602180A ES 9602180 A ES9602180 A ES 9602180A ES 2123432 A1 ES2123432 A1 ES 2123432A1
Authority
ES
Spain
Prior art keywords
soluble
polyhydroxylated
albumin
adduct
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES9602180A
Other languages
Spanish (es)
Other versions
ES2123432B1 (en
Inventor
Fernando Fussi
Victor Diaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex SA
Original Assignee
Syntex SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex SA filed Critical Syntex SA
Priority to ES9602180A priority Critical patent/ES2123432B1/en
Publication of ES2123432A1 publication Critical patent/ES2123432A1/en
Application granted granted Critical
Publication of ES2123432B1 publication Critical patent/ES2123432B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

Water-soluble adduct comprises polyhydroxylated trivalent iron complex with soluble desensitised albumin. The polyhydroxylated compound comprises a compound containing more than one hydroxyl group and capable of forming complexes with trivalent iron. The albumin has been subjected to finish treatment, alkali treatment and oxidation by solubilisation without affecting its molecular weight. The adduct is obtained by mixing the iron complex solution with the treated albumin solution.
ES9602180A 1996-10-15 1996-10-15 TRIVALENT IRON POLYHYDROXYLATED COMPLEX ADDUCTS WITH SOLUBLE ALBUMINE, METHOD OF OBTAINING, AND PHARMACEUTICAL AND DIETARY PREPARATIONS CONTAINING THEM. Expired - Fee Related ES2123432B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES9602180A ES2123432B1 (en) 1996-10-15 1996-10-15 TRIVALENT IRON POLYHYDROXYLATED COMPLEX ADDUCTS WITH SOLUBLE ALBUMINE, METHOD OF OBTAINING, AND PHARMACEUTICAL AND DIETARY PREPARATIONS CONTAINING THEM.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9602180A ES2123432B1 (en) 1996-10-15 1996-10-15 TRIVALENT IRON POLYHYDROXYLATED COMPLEX ADDUCTS WITH SOLUBLE ALBUMINE, METHOD OF OBTAINING, AND PHARMACEUTICAL AND DIETARY PREPARATIONS CONTAINING THEM.

Publications (2)

Publication Number Publication Date
ES2123432A1 true ES2123432A1 (en) 1999-01-01
ES2123432B1 ES2123432B1 (en) 1999-10-01

Family

ID=8296371

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9602180A Expired - Fee Related ES2123432B1 (en) 1996-10-15 1996-10-15 TRIVALENT IRON POLYHYDROXYLATED COMPLEX ADDUCTS WITH SOLUBLE ALBUMINE, METHOD OF OBTAINING, AND PHARMACEUTICAL AND DIETARY PREPARATIONS CONTAINING THEM.

Country Status (1)

Country Link
ES (1) ES2123432B1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2188336A1 (en) * 2000-10-18 2003-06-16 Tedec Meiji Farma S A Soluble albumin adducts with polyhydroxilated complexes (polyalcoholic) of trivalent iron, method for obtaining them and pharmaceutical and dietetic preparations that contain them.
EP1655308A1 (en) 2004-11-03 2006-05-10 Tedec-Meiji Farma, S.A. Adducts of soluble ovalbumin with trivalent iron polyalcohol complexes and method to produce them

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304183A1 (en) * 1987-08-20 1989-02-22 Biomedical Frontiers, Inc. Stabilization of deferoxamine to chelate free ions in physiological fluid
WO1990001295A1 (en) * 1988-08-04 1990-02-22 Advanced Magnetics, Incorporated Receptor mediated endocytosis type mri contrast agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304183A1 (en) * 1987-08-20 1989-02-22 Biomedical Frontiers, Inc. Stabilization of deferoxamine to chelate free ions in physiological fluid
WO1990001295A1 (en) * 1988-08-04 1990-02-22 Advanced Magnetics, Incorporated Receptor mediated endocytosis type mri contrast agents

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2188336A1 (en) * 2000-10-18 2003-06-16 Tedec Meiji Farma S A Soluble albumin adducts with polyhydroxilated complexes (polyalcoholic) of trivalent iron, method for obtaining them and pharmaceutical and dietetic preparations that contain them.
EP1655308A1 (en) 2004-11-03 2006-05-10 Tedec-Meiji Farma, S.A. Adducts of soluble ovalbumin with trivalent iron polyalcohol complexes and method to produce them
ES2258391A1 (en) * 2004-11-03 2006-08-16 Tedec-Meiji Farma, S.A. Adducts of soluble ovalbumin with trivalent iron polyalcohol complexes and method to produce them

Also Published As

Publication number Publication date
ES2123432B1 (en) 1999-10-01

Similar Documents

Publication Publication Date Title
EP0943331A3 (en) Formulations containing oxaliplatin
WO1998029110A3 (en) Formulation and method for treating neoplasms by inhalation
PL317105A1 (en) Compositions containing dna and p53 damaging agents
CA2263379A1 (en) Method for iron delivery to a patient by transfer from dialysate
CA2173457A1 (en) Use of 5-alpha reductase inhibitorsand compositions for treating androg enic alopecia
PL343164A1 (en) An iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, a process for producing said iron-dextran compound and use of said compound for the preparation of a parenterally administrable therapeutical composition
DE69736067D1 (en) Neue cryptophycin-derivate als antineoplastika
IL134259A0 (en) Use of physiologically acceptable vanadium compounds, salts and complexes
WO1999022722A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
EP2258702A3 (en) Purified compositions of 10-Propargyl-10-Deazaaminopterin and method of using same in the treatment of tumors
HU895608D0 (en) Process for the preparation of chelates containing ortho ligating functional group and complexes thereof
HUT56849A (en) Process for producing antibiotic complexes and chelates and pharmaceutical compositions comprising such active ingredient
ZA837857B (en) Platinum-diamine complexes,a process for the preparation thereof and a process for the preparation of a medical composition using such a complex for the treatment of cancer
ES2123432A1 (en) Formulation for oral delivery of iron complexes - comprises water-soluble adduct comprising polyhydroxylated trivalent iron complex with soluble albumin
EP1545479A4 (en) Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors
AU5170499A (en) Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis
AU2162700A (en) Supramolecular complexes containing therapeutic agents
EP0281070A3 (en) Pharmaceutical composition for the treatment of cancer
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
IL131959A0 (en) Pharmaceutical combined preparations containing erythropoietin and iron preparations
WO1999011256A8 (en) L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
ES2188336A1 (en) Soluble albumin adducts with polyhydroxilated complexes (polyalcoholic) of trivalent iron, method for obtaining them and pharmaceutical and dietetic preparations that contain them.
WO1997033620A3 (en) Compounds for treating tumours
WO1994020115A3 (en) Hyaluronic acid used as a cancer treatment
WO1993020852A3 (en) Macrocyclic chelating agents, chelates and conjugates thereof

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19990101

Kind code of ref document: A1

Effective date: 19990101

FD2A Announcement of lapse in spain

Effective date: 20170126